C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
C4 Therapeutics presented Phase 1 data for cemsidomide at the EHA 2026 Congress, showing a 53% overall response rate at the recommended Phase 2 dose in heavily pretreated multiple myeloma patients. The study included 73 patients with a median of seven prior lines of therapy, many of whom had received prior BCMA or CAR-T treatments. Responses deepened over time, with some patients achieving stringent complete responses and MRD negativity. The drug was generally well tolerated with manageable neutropenia and minimal dose reductions.
Key figures
- Drug Name
- cemsidomide
- Phase Of Trial
- Phase 1
- Orr 75ug
- 40%
- Orr rp2d
- 53%
- Orr all doses
- 36%
- Patient count
- 73
- Median prior lines
- 7
- Grade 3 4 neutropenia pct
- 58%
- Median duration of response months
- 7.9
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.